REFERENCES
- Scher M., Krieger J. N., Jurgens S. Am. J. Psychiatry 1983; 140: 1362–1363
- Lansky M. R., Selzer J. J. Clin. Psychiatry 1984; 45: 232–233
- Aranoff G. A. Lancet 1984; 856
- Medical Letter page 35, March 30, 1984
- Tyrer S. P., Weller M. P.I. Am. J. Psychiatry 1985; 142: 142–143
- Warner M. D., Peabody C. A., Harvey M. D., Whiteford A., Hollister L. E. J. Clin. Psychiatry 1987; 48: 244–245
- Fisbain D. A. J. Urology 1988; 139: 831
- Carson C. C., Mino R. D. J. Urology 1988; 139: 369–370
- The American Psychiatric Press Textbook of Psychopharmacology, A. F. Schatzberg, C. B. Nemeroff. Published by the American Psychiatric Press, Inc, Washington, DC 1995
- Rhodes C. T. Clinical Research and Drug Regulatory Affairs 1988; 15: 1–24
- Allen J., Rhodes C. T. Clinical Reaseach and Drug Regulatory Affairs 2000; 17: 27–34
- Adverse Drug Events (GAO-HEHS-00-21) GAO Report to Congressional Requeters, January 2000
- Adverse Events GAO-HEHS-00-61. Statement of Dr. Jane Heinrich, 3 February 2000
- Pharmacoepidemiology, L Strom Brian. 3rd Edition, Published by Wiley, New York, NY 2000
- Moore T. J., Psaty B., Furberg C. D. JAMA 1998; 279: 1571–1573
- Federal Registrar, Volume 44, No 124, Tuesday 26 June 1979, Section 63
- Pharmaceutical Reseach and Manufacturers White Paper of August 1999 titled. “Distribution of Product Information to the Product Dispensing Site Electronically”
- Pharmacist's Letter, Volume 16 No 7 July 2000